Invited Lectures

1. “Longitudinal HIV-1 Phylogenetic and Phylodynamic Transmission Analyses in Cyprus: The Cypriot HIV-1 Transmission Cohort Study (CHICS)”. 4th Annual Health Care Congress-2019. Marrakech, Morocco, April 27, 2019.


2. “Phylogenetic and Phylodynamic Analyses of the Cypriot HIV-1 Transmission Cohort Study (CHICS) from 1986 to 2012”. European Society for Translational Antiviral Research (ESAR), Scientific Spring Meeting. Rome, Italy, May 29, 2018.


3. “Scholarship and Leadership in Science: The Art and the Politics”. National Honor Society (NHS) Induction Ceremony, American International School in Cyprus (AISC). Nicosia, Cyprus, March 22, 2018.


4. “Current Therapies for HIV-1 Infection”. 3rd Pancyprian Student Conference on Molecular Biology, Biochemistry, Genetics and Cell Biology. Nicosia, Cyprus, February 17, 2018.


5. “Host and Viral Factors in HIV-1 Disease”. 6th Conference of the Cyprus Society of Human Genetics. Nicosia, Cyprus, November 24, 2017.


6. “HIV Disease: From Biology to Chemotherapeutics and Beyond”. 5th International Multi-thematic Scientific Bio-Medical Congress. Nicosia, Cyprus, November 4, 2017.


7. “The Development of Vaccines Using Genetically Engineered Inoviruses”. 15th Annual Summit on Vaccines and Immunization. Berlin, Germany, February 20, 2017.


8. “Engineering Antigen-Displayed Phage as Vaccines”. 4th World Congress on Targeting Infectious Diseases Phage Therapy. Paris, France, June 3, 2016.


9. “Transmission Patterns of Concurrent HIV-1 Subtype Epidemics Circulating in Cyprus ”. European Society for Antiviral Research (ESAR). Rome, Italy, May 24, 2016.


10. “Novel Vaccines Utilizing Antigen-Displayed Inoviral Vectors”. 7th Middle East-Global Summit on Vaccines & Vaccination. Dubai, UAE, September 28, 2015.


11. “Re-Engineering Inoviruses to Advance Vaccines Inducing Humoral and Cellular Responses: Implications in HIV-1 Vaccines”. The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem. Jerusalem, Israel, May 28, 2015.


12. “Development of Prophylactic Vaccines Against HIV-1”. Open University in London, London, UK, March 19, 2015.


13. “HIV-1 Disease: From Biology to Chemotherapeutics to Vaccines”. 10th Hellenic Conference in Virology, Athens, Greece, February 28, 2015.


14. “Viral Attack and Cellular Defense: Role of Human Genetics in the Biology of HIV-1 ”. Annual Conference of Cyprus Society of Human Genetics, Nicosia, Cyprus, January 9, 2014.


15. “Molecular Epidemiology of HCV Infection in Cyprus”. Annual Conference of Hepatology, Nicosia, Cyprus, March 3, 2012.


16. “Molecular Evolution of Human Immunodeficiency Virus Type-1 (HIV-1)”. 7th Congress of Biology Society, Limassol, Cyprus, April 6, 2011.


17. “Monitoring the HIV-1 Disease in Cyprus (1986 – 2010)”. 5th Congress of Clinical Chemistry and Laboratory Medicine, Limassol, Cyprus, March 19, 2011.


18. “Viral Universe”. The American International School in Cyprus, Nicosia, Cyprus, December 9, 2010.


19. “High Points of Virology Presented at the 17th Conference on Retroviruses and Opportunistic Infection (CROI)”. 16th International Symposium on HIV and Emerging Infectious Diseases, Marseille, France, March 26, 2010.


20. “HIV-1 Integrase Inhibitors: Role of Natural Genetic Diversity of Drug Efficacy and Resistance”. 2nd International Conference on Drug Discovery and Therapy, Dubai, United Arab Emirates, February 4, 2010.


21. “Spread of HCV among Intravenous Drug Users in Cyprus”, Press Conference on Infectious Diseases Associated with Intravenous Drug Users, Nicosia, Cyprus, December 15, 2009.


22. “Charles Darwin and the Theory of Evolution”, 200th Anniversary of Darwin’s Birth, Pallouriotissa Lyceum, Nicosia, Cyprus, December 11, 2009.


23. “Understanding the Molecular Basis of HIV Integrase Inhibitors by Molecular Modeling: Implications of HIV Natural Genetic Diversity on Drug Efficacy and Resistance”. Israeli AIDS Medical Society Conference, Ramot, Israel, November 27, 2009.


24. “Implications of HIV-1 Natural Genetic Diversity on Structure-Based Drug Design and Development of Drug Resistance”. Erasmus University Medical Center, Rotterdam, The Netherlands, October 29, 2008.


25. “Structured-Based Computational Analysis of the Implications of Subtype Specific Polymorphisms within M Group Strains on the Efficacy of HIV-1 Integrase Inhibitors”. 5th EuropeHIVResistance Meeting, Budapest, Hungary, March 25, 2008.


26. “Implications of Viral and Host Factors in HIV-1 Transmission and Pathogenesis”. Medical Society, Downing College of the University of Cambridge, UK, February 28, 2007.


27. “HIV-1 Infection in Cyprus: Where is Coming from and Where is Going to”. 2007 World AIDS Day, Nicosia, Cyprus, December 1, 2007.


28. “Quantifying Minority HIV-1 Drug Resistant Strains by Novel Assays Using Allele-Discriminating Polymerizing Molecular Beacons and Real-Time PCR Technologies”. 2007 4th EuropeHIVResistance Meeting, Zeist, Netherlands, October 16, 2007.


29. “Molecular Epidemiology of HIV-1 Infection in Cyprus and Spread of Resistance to Antiretroviral Drugs”. 2006 World AIDS Day, Nicosia, Cyprus, December 1, 2006.


30. “Molecular Beacon Technology: Host and Viral Factors in HIV-1 Transmission and Pathogenesis”. Department of Mechanical Engineering, University of Cyprus, November 1, 2006.


31. “Reservoir and Resistance: Implications of Cellular HIV-1 DNA Load in Resistance and Efficacy of Antiretroviral Therapy”. 2nd EuropeHIVresistance Meeting. Zandvoort, Netherlands, October 10, 2006.


32. “Host and Viral Correlates of HIV-1 Transmission and Disease Progression”. US National Institute of Health, DHHS 2006 NIAID Research Conference, Opatija, Croatia, 2006.


33. “Advances in HIV Virology”. 14th International Symposium on HIV and Emerging Infectious Diseases, Tulon, France, 2006.


34. “Multi-Allelic Detection of the Severe Acute Respiratory Syndrome-Associated Coronavirus (SARS-CoV) Using ‘Sloppy’ Molecular Beacons: A ‘Molecular Shotgun’ Approach of Recognizing a Moving Genetic Target”. 8th Hellenic Symposium of Virology, Thessalonica, Greece, 2006.


35. “HIV-1 Cellular Viral Load Pre- and Post-Antiretroviral Therapy”. 1st EuropeHIVresistance Meeting. Monte Carlo, Monaco, March 27, 2006.


36. “Cellular Viral Load Pre- and Post-Antiretroviral Therapy”. 2nd International Workshop on HIV Persistence During Therapy. Saint Martin, French West Indies, December 7, 2005.


37. “Η Επόμενη Πανδημία Γρίπης (Human Influenza Virus): Μαθήματα από την Φυσική Ιστορία της HIV Λοίμωξης”. Science Day, University of Cyprus. Nicosia, Cyprus, November 19, 2005.


38. “Implications of HIV-1 Cellular Viral Load in Resistance”. 9th SPREAD European Coordinators Meeting. Vinkeveen, Netherlands, November 1, 2005.


39. “Φυσική Ιστορία της λοίμωξης HIV: Από που Έρχεται και που Πηγαίνει”. Science Day, University of Cyprus. Nicosia, Cyprus, October 8, 2005.


40. “Natural History of HIV: The Role of Host Genetics in HIV Transmission and Disease Progression”. Open University of Greek Society in London. London, United Kingdom, April 21, 2005.


41. “Host Genetics in HIV Transmission and Pathogenesis”. 15th International AIDS Conference. Bangkok, Thailand, July 13, 2004.


42. “Implications of Host Genetics in HIV-1 Disease”. University of Toronto. Toronto, Canada, June 15, 2004.


43. “Detection & Quantification of the SARS-associated coronavirus”. 13th International Symposium on HIV & Emerging Infectious Diseases. Tulon, France, June 5, 2004.


44. “Impact of HIV-1 Cellular Viral Load on the Progression of HIV-1 Disease”. 1st International Workshop on HIV Persistence during Therapy. French West Indies, December 10, 2003.


45. “The Impact of Human Allelic Variation on HIV Disease”. The International Center for Public Health. Newark, USA, June 11, 2003.


46. “Rapid Molecular Identification of Pathogenic Agents: Detection of Bacillus anthracis (anthrax) Strains in Clinical Samples”. 4th Biomedical Symposium. Limassol, Cyprus, March 15, 2003.


47. “Viral and Host Determinants on HIV-1 Disease”. 4th Biomedical Symposium. Limassol, Cyprus, March 15, 2003.


48. “Molecular Beacons: An Emerging Technology for Molecular Diagnosis”. Hellenic Pasteur Institute. Athens, Greece, February 5, 2003.


49. “Impact of Cellular HIV-1 Viral Load on the Progression of HIV-1 Disease”. XIV International AIDS Conference. Barcelona, Spain, July 11, 2002.


50. “Use of Molecular Beacons and Multi-Allelic Rapid-Cycle Real-Time PCR for Detection of and Discrimination between Virulent Bacillus anthracis and Other Bacillus Isolates in Clinical Samples”. Conference for Bio-terrorism in Greece. Hellenic Center for Infectious Disease Control of the Ministry of Health. Athens, Greece, May 10, 2002.


51. “Quantification of Minor Populations of Drug-Resistant HIV-1 Isolates by a Selective Amplification Assay Using Fluorescence-Based Real-Time PCR and Allele-Discriminating Oligonucleotides”. 3rd International Workshop on Structured Treatment Interruptions. Montreal, Canada, March 23, 2002.


52. “Molecular Detection and Genetic Characterization of Bacillus anthracis (anthrax) by a Rapid Assay Using Real-Time PCR and Molecular Beacons”. Center for Disease Control, Ministry of Health, Greece. Athens, Greece, November 21, 2001.


53. “The Implications of Host Genetics for the Transmission of HIV-1 and the Progression of HIV-1 Disease”. 6th Hellenic Biomedical Congress. Athens, Greece. October 12, 2000.


54. “Natural History of HIV and the Historical Advancements on Treatment and Vaccine Development”. 3rd Symposium for Clinical Laboratory Subjects. Limassol, Cyprus, March 18, 2000.


55. “Impact of Natural CCR5 Polymorphisms and Recent Thymic Emigrants on HIV-1 Disease”. University of Massachusetts Medical School Worcester, USA. January 12, 2000.


56. “Effects of CCR5 Allelic Variants and the Thymus on HIV-1 Disease”. College of Physicians and Surgeons, Columbia University. New York, USA, December 13, 1999.


57. “Molecular Beacons: Gene Quantification and Allele Discrimination”. ViroLogic South San Francisco, USA, November 5, 1999.


58. “The role of Alpha-1 T cell Receptor Excisional Circles (α1 TREC) in HIV-Disease Progression”. Viral Epidemiology Branch, National Cancer Institute. Frederick, USA, July 20, 1999.


59. “Impact of Chemokine Receptor Polymorphisms on Vertical Transmission”. Teratology Society: HIV Infection During Pregnancy. Keystone, USA, June 29, 1999.


60. “Spectral Genotyping of Chemokine Receptor Polymorphisms”. CCR5 AIDS Symposium: Genetic Consequences of CCR5 Promoter Variants on AIDS at The National Cancer Institute. Frederick, USA, April 30, 1999.


61. “The Role of Natural Chemokine Receptor Polymorphisms in HIV-1-Induced Disease”. Second National Symposium on AIDS and Sexually Transmitted Decease Athens, Greece. April 23, 1999.


62. “Human Genetic Variation and HIV”. Baruch College, City University of New York. New York, USA. February 18, 1999.


63. “Polymorphisms in the Regulatory Region of the CCR5 Influence Perinatal Transmission of HIV”. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, February 2, 1999.


64. “Polymorphisms in the Regulatory Region of the CCR5: Influence on Perinatal Transmission of HIV-1”. Pediatric AIDS Clinical Trial Group (ACTG). Washington DC, USA, December 7, 1998.


65. “The Impact of Chemokine Receptor Polymorphisms on HIV Disease”. The Treatment Action Group. New York, USA, October 6, 1998.


66. “HIV-1 Variation”. The Sophie Davis School of Biomedical Education, City University of New York. New York, USA, June 3, 1996.


67. “Molecular Epidemiology of HIV infection in Cyprus”. Gregorian AIDS Foundation. Nicosia, Cyprus, March 15, 1996.


68. “Neutralization Serotypes of HIV-1”. First National Symposium on AIDS and Sexually Transmitted Decease. Thessaloniki, Greece, March 8, 1996.


69. “Global Genetic Variability of HIV-1: Implications for Vaccine Development”. Baruch College, City University of New York. New York, USA, February 29, 1996.


70. “Genetic Subtypes and Neutralization Serotypes of HIV-1”
Public Health Research Institute. New York, USA, February 6, 1996.


71. “Genetic Analysis of HIV-1 Strains from Patients in Cyprus”. 3rd Cypriot Conference on AIDS. Nicosia, Cyprus. December 3, 1995.